Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-694-4
CAS number: 14644-61-2
Acute toxicity: oralOne reliable study was available and defined an LD50 of 3500 mg/kg bw in rats for zirconium sulfate (Cochran et al., 1950).Acute toxicity: inhalationNo study needs to be conducted as the substance is classified as corrosive to the skin.Acute toxicity: dermalNo study needs to be conducted as the substance is classified as corrosive to the skin.
Acute oral toxicity
Cochran et al. (1950) observed an acute oral LD50 of 3500 mg/kg bw (1253
mg Zr/kg bw) when zirconium sulfate was administered by oral gavage to
Sprague-Dawley rats. The time of death varied from a few hours to a few
days following the exposure to the test substance. Few deaths were
reported later than five days after exposure to test substance.
Individual animal data were not provided. Animals exposed to the test
substance showed a progressive depression and decrease in activity until
death occurred. No gross pathological changes were reported in any of
the animals receiving lethal doses of the test substance. No
physiological changes were reported in any of the animals receiving
lethal doses of the test substance. Further, the same study reported an
acute oral LD50 of 10000 mg/kg bw for the related substance sodium
Acute inhalation toxicity
An acute inhalation study does not need to be conducted as the substance
is classified as corrosive to the skin (according to REACH Annex VIII
section 8.5, column 2).
Acute toxicity: dermal
An acute dermal study does not need to be conducted as the substance is
classified as corrosive to the skin (according to REACH Annex VIII
section 8.5, column 2).
Acute toxicity: other routes
Cochran et al. (1950) observed an acute LD50 of 175 mg/kg bw and 4100
mg/kg bw when zirconium sulfate and
sodium zirconyl sulfate, respectively, were administered to rats by
intraperitoneal injection. These studies were considered as supporting
studies only, since intraperitoneal injection is not a normal exposure
pathway and absorption of zirconium via realistic pathways (oral,
dermal, inhalation) is expected to be extremely low.
Based on the available data and according to the DSD/CLP criteria
zirconium sulfate should not be classified for acute toxicity via the
oral route of exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Damit Sie die Website optimal nutzen können, verwenden wir Cookies.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again